Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S, Xu Y, Chen CI, Cope S, Mojebi A, Kuznik A, Konidaris G, Ayers D, Sasane M, Allen R, Huynh TM, Popoff E, Freeman M, Andria ML, Fury MG, Singh K, Stockfleth E, Challapalli A, Schmults CD. Keeping S, et al. Future Oncol. 2021 Feb;17(5):611-627. doi: 10.2217/fon-2020-0823. Epub 2020 Oct 14. Future Oncol. 2021. PMID: 33052055 Free article.
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A, Smare C, Chen CI, Venkatachalam M, Keeping S, Atsou K, Xu Y, Wilson F, Guyot P, Chan K, Glowienka E, Konidaris G. Kuznik A, et al. Among authors: keeping s. Value Health. 2022 Feb;25(2):203-214. doi: 10.1016/j.jval.2021.08.009. Epub 2021 Oct 16. Value Health. 2022. PMID: 35094793 Free article.
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50.
Freemantle N, Xu Y, Wilson FR, Guyot P, Chen CI, Keeping S, Konidaris G, Chan K, Kuznik A, Atsou K, Glowienka E, Pouliot JF, Gullo G, Rietschel P. Freemantle N, et al. Among authors: keeping s. Ther Adv Med Oncol. 2022 Jun 16;14:17588359221105024. doi: 10.1177/17588359221105024. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35747163 Free PMC article.
Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.
Black CM, Keeping S, Mojebi A, Ramakrishnan K, Chirovsky D, Upadhyay N, Maciel D, Ayers D. Black CM, et al. Among authors: keeping s. Front Oncol. 2022 Apr 28;12:868490. doi: 10.3389/fonc.2022.868490. eCollection 2022. Front Oncol. 2022. PMID: 35574411 Free PMC article.
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Jairath V, et al. Among authors: keeping s. Expert Rev Gastroenterol Hepatol. 2021 Jun;15(6):711-722. doi: 10.1080/17474124.2021.1880319. Epub 2021 Mar 4. Expert Rev Gastroenterol Hepatol. 2021. PMID: 33599181 Free article.
36 results